AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Xilio Therapeutics, Inc. Director's Dealing 2021

Oct 22, 2021

34726_dirs_2021-10-21_d4a44319-ebf8-43c1-bd6b-52793de7f235.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-21

Reporting Person: Bonstein Sara (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$11.69	2031-08-22	Common Stock (53213)		Direct

Footnotes

F1: The option was granted on August 23, 2021 for 53,213 shares. One-third of the shares underlying the option shall vest on August 5, 2022, August 5, 2023 on August 5, 2024, respectively.